What is Plexium?
Plexium operates at the vanguard of precision medicine, specializing in the identification of small molecules that modulate E3 ligases. The company's core competitive advantage lies in its DELPhe platform—a sophisticated DNA-Encoded Library phenotypic screening system. By utilizing advanced droplet and microwell confinement, Plexium miniaturizes cell-based assays to achieve unprecedented throughput and high-content data readouts at a fraction of traditional costs. This technological infrastructure positions the firm as a critical player in the next generation of targeted protein degradation, a field currently experiencing rapid clinical and commercial expansion.
How much funding has Plexium raised?
Plexium has raised a total of $225.1M across 4 funding rounds:
Series A
$28M
Other Financing Round
$35M
Other Financing Round
$102M
Stock/Share Issuance
$60.1M
Series A (2019): $28M with participation from The Column Group, DCVC Bio, Neotribe Ventures, CRV, and M Ventures
Other Financing Round (2021): $35M led by The Column Group, DCVC Bio, Lux Capital, and PIVOTAL BIOVENTURE PARTNERS LLC
Other Financing Round (2022): $102M supported by RA Capital Management, TCG X, Pappas Capital, L.P., BVF Partners, Surveyor Capital, and Softbank Vision Fund 2
Stock/Share Issuance (2025): $60.1M, investors not publicly disclosed
Key Investors in Plexium
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that nurtures platforms from inception to exit.
DCVC Bio
DCVC Bio is a deep tech venture capital firm that leverages artificial intelligence to unlock potential in biotechnology, supporting ambitious founders tackling global challenges.
Lux Capital
Lux Capital is a venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, backing frontier areas including biotechnology.
What's next for Plexium?
With the infusion of this latest capital, Plexium is well-positioned to transition from a platform-centric organization to a clinical-stage powerhouse. The strategic roadmap likely involves the advancement of lead candidates into human trials while further refining the DELPhe screening capabilities to explore novel biological targets. As the company scales, the focus will shift toward establishing high-value pharmaceutical partnerships and optimizing its internal R&D workflows to maintain its leadership in the competitive landscape of small molecule therapeutics. The sustained support from top-tier life science investors provides the necessary runway to navigate the complexities of drug development and achieve long-term commercial viability.
See full Plexium company page
